Healthcare · NYSE/NASDAQ: MRK
Merck & Co. Inc.
Drug Manufacturers
Market Cap $300.00B
Verdict: High
Quality Scores
Multi-Bagger
72/100
Compounder Quality
87/100
Management Credibility
86/100
Governance
92/100
Cash Flow Quality
91/100
AI Summary
Merck & Co. (MRK) demonstrates a bifurcated strategic profile characterized by the massive commercial success of Keytruda and a transitioning R&D pipeline. Revenue has scaled from $42.29B in 2018 to over $65B by 2025, representing a steady upward trajectory despite patent cliffs. The company's financial profile was distorted in 2023 by the $10.8B Prometheus acquisition treatment, which resulted in a temporary collapse of net income to $365M, followed by a sharp recovery. Equity has rebounded from a 2020 low of $25.32B to $52.61B, signaling strong internal accruals and balance sheet repair.…
Top Opportunities
- Market leadership in oncology through Keytruda
- Strong pricing power in specialty vaccines (Gardasil)
- Excellent cash conversion ratio (OCF/PAT)
Top Risks
- Extreme revenue concentration in Keytruda (LOE risk 2028)
- High regulatory scrutiny on drug pricing in the US
- Massive net income volatility due to acquisition charges
Latest report: Read the annual report summary →
Unlock the full report
Full sections, financial charts, AI chat and PDF export are available with Premium.